Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NGR015 phase III trial of NGR-hTNF plus best investigator's choice versus placebo plus best investigator's choice in previously treated malignant pleural mesothelioma
NL-OMON37673Phase 3Active, not recruiting
- Sponsor
- Innopharma
- Start
- Jun 2012
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pleural mesothelioma comparing NGR-hTNF + BSC ± single-agent chemotherapy with Placebo + BSC ± single-agent chemotherapy (2 arms). Primary endpoint: Overall survival. Started Jun 2012; status: active, not recruiting.
02
Drugs
NGR-TNF
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on NL-OMON37673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37673.